Bioventus, Inc. Class A BVS

Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Bioventus stock has delivered strong share price gains over the past few years, yet current valuation checks still suggest it screens as relatively cheap on several metrics. That combination of a big historical return with an apparently supportive valuation is what current and prospective shareholders are trying to interpret. Over the last 3 years Bioventus has returned about 198%, which puts a spotlight on whether the current price already reflects much of the good news that investors...